← FDA Drug Approvals (Drugs@FDA)

RIFABUTIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: I3 PHARMS · Approved 2026-03-19

Drug application

FDA Application #

ANDA212430

Application type

Abbreviated New Drug Application (Generic)

Brand name

RIFABUTIN

Generic name

RIFABUTIN

Active ingredients

RIFABUTIN

Dosage form

CAPSULE

Route

ORAL

Marketing status

Prescription

Sponsor

I3 PHARMS

Manufacturer

i3 Pharmaceuticals, LLC

First approval

2026-03-19

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown